21CC Oncology Intelligence (Issue 18): Olaparib approved by EU for the treatment of early breast cancer; Merck K drug two combination therapy studies fail


2022-08-08: [Chinese Article Link]  You can receive the latest information every week in the field of oncology. 21CC (cancer care), we are concerned with all cancer-related matters. The Innovative Information Program of the New Health Institute for the 21st Century - 21CC Information on Oncology, collating a week-long information on tumours, focusing on cancer prevention, early diagnosis and treatment, and working with the health of the King. I. New medicines (new adaptives/technology) approved The European Commission approved the PARP inhibitor Orapali as an ancillary treatment for adult breast cancer patients On 5 August, Aslikon and Mercado jointly announced that the European Commission (EC) had approved the PARP inhibitor Orapari (olaparib, English commercial name Lynparza) as an ancillary treatment for adult breast cancer patients. Orapali can be used either as a single drug or as a combination of endocrine therapy; these patients are at-risk early breast cancer patients who have undergone new or assisted chemotherapy, have mutated embryonic BRCA1/2 mutations, and their tumours are negative for the human skin growth factor (2 HER2). This approval was based on the positive results of the Olympia experiment, published in the New England Medical Journal in June last year, which was a three-stage clinical experiment with blind, parallel group design and placebo as a control group. The aim is to test the efficacy and safety of Olapali as an ancillary treatment for those who are at high risk of breast cancer, who have completed partial treatment and new or assistive chemotherapy with embryonic BRCA1/2 mutation and HER2 negative tumours. II. Research and development/clinical progress Mercerton's two joint treatment studies failed. Recently, Meshadong announced that KEYNOTE-921, a third phase of the KEYNOTE-921 study, using the Dositas association to treat transfer resistance prostate cancer (mCRPC) patients, did not reach the two main endpoints of the total survival period (OS) and the lack of progress in video science (RPFS). The results of the KEYNOTE-921 study show that while there is an improvement in the number of OS and RPFS patients receiving Keytruda+Dosita+Punesson treatment compared to the control group, the results are not statistically significant. The safety of the experiment was consistent with what had been observed in previous studies, the detailed results of which would be published at a forthcoming medical conference. Also on 3 August, Meshadong/Guide announced that the three-phase LEAP-002 study for the treatment of late uncut liver cell cancer (uHCC) on the link of the Keytruda (Paboli Pearl Mono) to Lenvima (Lundeni) had not reached the two main endpoints of the total survival (OS) and the no-progress survival (PFS). The results show that while there has been an improvement in the number of OS and PFS patients treated with the Paboli Pearl Unit + LNDS, the results are not statistically significant. The safety of the experiment is consistent with what has been observed in previous studies. Gmida Cell is eligible for FDA priority review for stem cell therapy Recently, Gamida Cell announced that the United States FDA had processed BLA applications for a biological product licence (BLA) for the treatment of blood cancer requiring stem cell transplants of the same species. Omidubicel is an active stem cell therapy with the potential of “first-in-clas” for treating malignant neoplasms in the blood system. According to the press release, it was the first bone marrow transplant treatment product to be recognized by the United States FDA breakthrough therapy, and has been certified as an orphan in both the United States and the European Union. In response to this BLA application, the United States FDA has granted eligibility for a priority review and set a target date of 30 January 2023 for the review of the Prescription Drug User Fees Act (PDUFA). In the United States, FDA applies for priority review for products that demonstrate significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of diseases. Notice of approval for HUNS medicine for clinical trials with HLS-4642 injection liquid drugs On 2 August, according to the Heung Swe Medical Notice, the company received approval from the National Drug Control Authority for the issuance of a Notice of Approval for Clinical Trials of Drugs for HRS-4642 injection fluids, which will be conducted in the near future. HRS-4642 Injecting fluids inhibit the growth of oncological cells and act as an anti-cancer function, and there is currently no access to clinical and sales data on the same drugs available in the country and abroad. FDA suspends Beam's application for a clinical trial of CAR-T therapy based on base editor Recently, Beam Therapeutics, a base editor, announced that its BEAM-201 IND application had been suspended by FDA. The FDA will provide more detailed information on this decision within 30 days, and Beam is committed to updating it in a timely manner as more detailed information becomes available. BEAM-201, developed by Beam Therapeutics, is a four-heavy base-based CAR-T therapy for CD7 targets based on the twin platinum editor (Cytosine Base Editor, CBE), designed specifically for the same species, CAR-T cells. In June of this year, the treatment was presented to the FDA for the treatment of relapsed or incurable T-ALL (acute Tlymphocyte leukaemia) and other CD7 malignant tumours, the first of which was the co-editor of four genes. The Chinese team found new potential targets for oncological immunotherapy. On 5 August, according to information from the Chinese University of Science and Technology, the team of Professor Zhou Yongbin of the Ministry of Life Sciences and Medicine and the team of Professor Jiangwei, in collaboration with the National Priority Laboratory for Transforming Medicine and Innovative Medicines, identified new potential targets for oncological immunotherapy. The study, published online in Science magazine on 4 August, in which researchers studied the role of the nerve stress centre in oncological immunity by constructing different oncology models, discovered the hypothalamus-trillus axis and the hormones it produced, α-MSH, which could contribute to the growth of tumours by promoting marrow blood and immunosuppressive marrow cells through its receptor MC5R, which is expected to be a potential new target for immunotherapy treatment of tumours. III. Financing and cooperation for oncology investment Sengine Precision Medicine received $10 million in A2 round financing to promote individualized cancer treatment In recent days, Sengine Precision Medicine, a precision oncology company based in Seattle, announced the completion of a $10 million A2 round of financing, which to date has totalled $19 million. Sengine Precision Medicine is a precision oncology company that uses patient-specific oncology cells to pre-test drugs on 3D cultures and to develop new cancer therapy. Sengine, the world-renowned derivative of the Fred Hutchinson Cancer Research Centre, has more than 20 years of research and development experience in diagnosis and drug discovery. The company is commercializing the PARIS tests, a next-generation diagnostic test for predicting drug response that combines knowledge of cancer genomics with the prototype tests of living cells derived from patients, using robotic techniques and know-how algorithms. Novasenta completed $40 million A-round financing for the development of new immuno-cancer candidate drugs Recently, Novasenta announced the completion of a $40 million A round of financing, led by a venture capital company, UPMC Enterprises. This funding will enable Novasenta to advance its antibody-based treatment, expand its proprietary computing platform for target discovery and continue to recruit top talent. The company’s team is using the human oncology micro-environment to develop new immunotherapy to enable humans’ own immune systems to combat cancer. The company has developed an exclusive platform for single-cell RNA analysis of human tumour samples that combines advanced data mining and target validation capabilities to accelerate the process from discovery to drug development. Inventive, venture capital co-directed, and the original creatures completed more than $120 million in B-round financing. In recent days, Innovative Biopharmaceuticals had announced the completion of a B round of financing totalling more than $120 million, which had been co-financed by pioneer and spring capital, with new investors in the Shanghai Initiative Fund, Kenichi Capital (the original drug capital), Suzhou Fund, Bozo Capital and a number of international investment funds, and the continued growth of new and emerging investments by old shareholders. This round of financing will be used primarily to facilitate the development and commercialization of more than a dozen fully conceptualized (POC) oncology treatment products, to continue to improve the construction of an autonomous corporate innovation technology platform, and to plan and build future commercial production bases. IDRx announced the completion of $122 million in round A financing, focusing on accurate cancer treatment. On 3 August, IDRx announced the completion of $122 million in round A financing. Building on the successful experience of therapeutic combination anti-cancer therapy and cocktail therapy in the treatment of cystic fibrosis and viral infections, IDRx aims to develop a highly selective, rationally designed combination of drugs to overcome the current limitations of precision anti-cancer drugs and to help more patients to achieve a more durable reduction in the early stages of the disease. The strategy of IDRx is to use combination therapy when cancer cells have not accumulated much mutation, which includes powerful targets to the main cancer-driven factors, and drugs to stop cancer cells from escaping. Conkwanda completes a new round of finance. Recently, Conwanda, the research and development developer of the soluble cancer virus, announced the completion of a new round of financing and strategic partnership introduction, with the participation of the East Heath Business Group, Chinese capital and the Blue Mountain Investment. It is understood that funds from this round of financing have been used mainly for technical development work such as clinical research and follow-up guidance virus product development for the new generation of cancer virus pipeline products in Conwanda. Konwanda Medical Science and Technology Ltd., Hangzhou, was established in February 2012 to work on the development of innovative drugs and treatments for somatic virus under the oncological immune theory, and Conwanda currently has seven somatic virus pipelines. Pan-Eun-Bio completes nearly a billion Pre-A round of financing. In recent days, the Guangzhou Pann Biotech Ltd. has completed nearly a billion yuan Pre-A round of financing. This round of financing will be financed by Chinese capital, Siovo, the Yabo pharmaceutical industry, and Japanese capital as an exclusive financial adviser, and will be used mainly for the IIND declaration and phase I clinical trials of multi-cell therapy products. The “Panese Organism” is mainly involved in the development of drugs for the treatment of oncology and related operations, and has developed autonomously a number of products for the treatment of oncology T-cells, as well as accurate screening of diagnostic reagents for the effective population of immunotherapy. He's working with Marengo Therapeutics. On 2 August, Ipsen and Marengo Therapeutics announced strategic cooperation to co-operate with Marengo's two pre-clinical selective T-cell receptor (TCR) activations. This collaboration will combine the expertise of Marengo in activating the T-cell innovation mechanism and the capacity for global oncology clinical development and commercialization. According to the agreement, Marengo will lead pre-clinical development activities until IIND applications are submitted to FDA in the United States, and Lippson will be responsible for clinical development and subsequent commercialization activities. Poseida Therapeutics entered into a partnership with Rhodes to develop a “ spot-based” CAR-T therapy On 4 August, Poseida Therapeutics announced a strategic cooperation and licensing agreement with Roche to cooperate in the development of the “sphere-type” amphibious CAR-T therapy for multiple osteoporomas, B-cell lymphoma and other blood adaptive disorders. Under this agreement, Poseida would receive an advance of $110 million, as well as recent milestones up to $110 million and other payments. Together with future development and commercialization milestones, Poseida would receive payments totalling up to $6 billion. Rhodes, on the other hand, will be given exclusive rights or options from Poseida for the development and commercialization of many Poseida projects on hemodynamic tumours of the same species, CAR-T, which include a clinical trial of the same species, CAR-T therapy P-BCMA-ALLO1, used for the treatment of multiple osteoporomas, as well as a projected IIND licence for the treatment of B-cell lymphoma in 2023, with the same species's double-targeting of CAR-T therapy P-CD19CD20-ALLO1. IV. 21CC week perspective Noise lymphoma is the first drug in Asia. Recently, Tafasitamab, an innovation for the treatment of lymphoma in Nouchen, has officially landed at the Hainan Hospital (hereinafter referred to as “Richin Hainan Hospital”) attached to the University of Shanghai Transport School of Medicine. At the same time, Tafasitamab opened in the vanguard of Bounty City and completed the first domestic injection at the Reginanan Hospital for a eligible Big B-cell lymphoma patient. “Tafasitamab’s initiative in Leisure City means that this innovative drug is being used for the first time in China to treat patients.” Dr. Choi Xiaozon, founder, chairman, and chief executive officer of the Nokchen Kenhua coalition, told the 21st Century economic reporter that it is a reflection of the full use of Lei Town’s concession policy, which allows more patients to benefit from Bo. Nocheng Kenhua is also in the process of submitting applications for the listing of new drugs in Hong Kong and Australia, which, once approved in Hong Kong and Australia, will benefit patients in the greater Gulf region, and is actively promoting the joint registration test of Tafasitamab in China, approved by the National Drug Control Service, while actively exploring the joint use of Obutoni and Tafasitamab. Professor Zhao Weiye Zhao, Vice-President of the Reginald Hospital, informed the 21st Century Economic Reporter that Tafasitamab was the new CD19 anti-innovation drug and that the first Asian patient had been reached by the Rigkin Hainan Hospital. In conjunction with the People's Hospital of Hainan Province, the Raking Hospital has established a national regional medical centre in Bojang, taking advantage of the policy advantages of the Pioneer City policy in Hainan. The hospital is a leading Chinese user of the new global medicine, a global promoter of the new Chinese medicine, a provider of the best medical care programme and a pioneer in the progress of clinical medicine worldwide. According to Lei Xiaorei, a member of the party committee and deputy director of the Lei Town Precinct Administration, to the 21st Century Economics Reporter, the company, including Noo Jianhua, has chosen Lei-City because of the gradual dividends of the Lei-City First Test policy, supported by health-related actions such as the Hainan Pharmacy Bureau, the National Pharmacy Bureau and the National Commission for Health Care, and especially since the establishment of the Le-Congree Administration, the Le-Congree Pre-Congree has made a “acccelerator” in the area of medical health, moving from a policy high to an industry-intensive “platform high ground”. “On this platform, the pharmaceutical industry, medical institutions and medical experts are actively involved and working closely together to bring the world's most advanced and innovative medical products, technologies and programmes to Le Lui City to meet the health needs of the population and to address the accessibility and affordability of medicines used by patients. The incidence of liver cancer in the stomach is underestimated, MUC 19 or an important biomarker. Recently, the internationally renowned journal, Chancer Communification (Impact Factors 15.28), published online a recent study by Professor Liu Tianshu of Nakayama Hospital, affiliated with the University of Khatami, in conjunction with the Medical Services, on the genetic mapping of the liver cancer in China and the important biomarker point MUC19, which drew molecular characteristics and development mechanisms for gastric hepatic cancer based on extraneous group data and provided important biological markers for the diagnosis and treatment of liver cancer in the stomach. Hepatitis cancer is known to be a rare but highly malignant form of stomach cancer, accounting for 0.3 to 1% of stomach cancer. In contrast to stomach cancer, hepatitis cancer is highly invasive, and patients are prone to liver and lymphosis, with very poor prognosis, with a 5-year survival rate of only 9%. Due to the low incidence of liver cancer in the stomach and its low clinical prevalence, it is rarely studied in depth, there is currently no standard treatment for liver cancer in the stomach, and the mechanisms for its occurrence are not well known. The above-mentioned study of this important biomarker MUC19 will probably boost the diagnosis and treatment of liver cancer in the stomach. To the twenty-first century economic report, Dr. Cumbung, a medical bioinformation scientist, told the economy that the current incidence of liver cancer in the stomach is understated and found that this biomarker is conducive to the diagnosis of patients who simply take blood for a rapid screening test to see if there is a mutation in the MUC19, which is equivalent to a diagnostic indication of a tumor that could become a cancer in the stomach liver. VI. Oncology knowledge point - hot target resolution CC21 will continue to launch the popular target study entitled " Review of the Clinical Study of New Anticancer Medicines in China 2021 ", published jointly by the Specialized Committee for Clinical Research on Anticancer Medicine of the China Society for the Advancement of Medical Innovation and the Heisco Research Foundation of Beijing. The above-mentioned associations and foundations aim to promote sound investment and research and development by investors and research and development institutions through annual reviews, by avoiding “high-level duplication” of overinvestment in popular areas and by paying attention to innovative areas that can fill clinical gaps, thereby optimizing the allocation of resources for research and development of new medicines for the sustainable development of China's pharmaceutical innovation industry. CCD7 1. Target mechanism Protein hormones associated with cell break-up cycle 7 (cell division cycle 7, CDC7) are a silicone/sultanic acid stimulant enzyme from yeast to humans, which plays a key role in the start-up of each replication starting point by being activated in conjunction with the active sub-unit Dbf4/S Ease Activator (ASK). There is growing evidence that CDC7 plays an important role in tumor cells, induces cell growth and may be associated with the prognosis of multiple malignant tumours. The CDC7 has been found to be highly expressed in the gelatinous breast tumor (GBM), which is associated with the poor prognosis of GBM patients. In addition, CDC7 induces radio-resistance from GBM cells, and CDC7 increases cell failure when it is removed from radiotherapy. CDC7 regulates the expression of DNA fix/reassemble 54L (RAD54L) by regulating RAD54L start-up activity. In treatment, CDC7 inhibitors inhibit the growth of tumor cells both in the body and in the body. 2. Overview of clinical research declarations A number of clinical studies on CDC7 targets are under way internationally, including Simurosertib (TAK-931), AS-0141, XL-413 but mostly I or I/II. At present, there are only very clean CDC7 inhibitors in the country who are conducting clinical studies for TQB3824 on safety and pharmacodynamic I among late-stage malignant tumour subjects. 3. Summary remarks There are currently fewer CDC7 targets for clinical research in the country, there are already distributed CDC7 inhibitors in domestic enterprises, such as redo medicine, and new generations of metabolic and stable CDC7 inhibitors still need more research and exploration to meet clinical needs. From impact mechanism analysis, CDC7 combined inhibitor treatment has the potential to reverse therapeutic resistance, and if combined DNA damage repair circuit inhibitors are likely to combine anti-cancer resistance, they can be actively explored in parallel with the accumulation of preliminary data during the single drug I period. (Revisitor, Beijing University Oncology Hospital, Gong Jiefan)


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.




Trending Topics


Trending News

What China Reads


21CC Oncology Intelligence (Issue 18): Olaparib approved by EU for the treatment of early breast cancer; Merck K drug two combination therapy studies fail


2022-08-08: [Article Link]  You can receive the latest information every week in the field of oncology. 21CC (cancer care), we are concerned with all cancer-related matters. The Innovative Information Program of the New Health Institute for the 21st Century - 21CC Information on Oncology, collating a week-long information on tumours, focusing on cancer prevention, early diagnosis and treatment, and working with the health of the King. I. New medicines (new adaptives/technology) approved The European Commission approved the PARP inhibitor Orapali as an ancillary treatment for adult breast cancer patients On 5 August, Aslikon and Mercado jointly announced that the European Commission (EC) had approved the PARP inhibitor Orapari (olaparib, English commercial name Lynparza) as an ancillary treatment for adult breast cancer patients. Orapali can be used either as a single drug or as a combination of endocrine therapy; these patients are at-risk early breast cancer patients who have undergone new or assisted chemotherapy, have mutated embryonic BRCA1/2 mutations, and their tumours are negative for the human skin growth factor (2 HER2). This approval was based on the positive results of the Olympia experiment, published in the New England Medical Journal in June last year, which was a three-stage clinical experiment with blind, parallel group design and placebo as a control group. The aim is to test the efficacy and safety of Olapali as an ancillary treatment for those who are at high risk of breast cancer, who have completed partial treatment and new or assistive chemotherapy with embryonic BRCA1/2 mutation and HER2 negative tumours. II. Research and development/clinical progress Mercerton's two joint treatment studies failed. Recently, Meshadong announced that KEYNOTE-921, a third phase of the KEYNOTE-921 study, using the Dositas association to treat transfer resistance prostate cancer (mCRPC) patients, did not reach the two main endpoints of the total survival period (OS) and the lack of progress in video science (RPFS). The results of the KEYNOTE-921 study show that while there is an improvement in the number of OS and RPFS patients receiving Keytruda+Dosita+Punesson treatment compared to the control group, the results are not statistically significant. The safety of the experiment was consistent with what had been observed in previous studies, the detailed results of which would be published at a forthcoming medical conference. Also on 3 August, Meshadong/Guide announced that the three-phase LEAP-002 study for the treatment of late uncut liver cell cancer (uHCC) on the link of the Keytruda (Paboli Pearl Mono) to Lenvima (Lundeni) had not reached the two main endpoints of the total survival (OS) and the no-progress survival (PFS). The results show that while there has been an improvement in the number of OS and PFS patients treated with the Paboli Pearl Unit + LNDS, the results are not statistically significant. The safety of the experiment is consistent with what has been observed in previous studies. Gmida Cell is eligible for FDA priority review for stem cell therapy Recently, Gamida Cell announced that the United States FDA had processed BLA applications for a biological product licence (BLA) for the treatment of blood cancer requiring stem cell transplants of the same species. Omidubicel is an active stem cell therapy with the potential of “first-in-clas” for treating malignant neoplasms in the blood system. According to the press release, it was the first bone marrow transplant treatment product to be recognized by the United States FDA breakthrough therapy, and has been certified as an orphan in both the United States and the European Union. In response to this BLA application, the United States FDA has granted eligibility for a priority review and set a target date of 30 January 2023 for the review of the Prescription Drug User Fees Act (PDUFA). In the United States, FDA applies for priority review for products that demonstrate significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of diseases. Notice of approval for HUNS medicine for clinical trials with HLS-4642 injection liquid drugs On 2 August, according to the Heung Swe Medical Notice, the company received approval from the National Drug Control Authority for the issuance of a Notice of Approval for Clinical Trials of Drugs for HRS-4642 injection fluids, which will be conducted in the near future. HRS-4642 Injecting fluids inhibit the growth of oncological cells and act as an anti-cancer function, and there is currently no access to clinical and sales data on the same drugs available in the country and abroad. FDA suspends Beam's application for a clinical trial of CAR-T therapy based on base editor Recently, Beam Therapeutics, a base editor, announced that its BEAM-201 IND application had been suspended by FDA. The FDA will provide more detailed information on this decision within 30 days, and Beam is committed to updating it in a timely manner as more detailed information becomes available. BEAM-201, developed by Beam Therapeutics, is a four-heavy base-based CAR-T therapy for CD7 targets based on the twin platinum editor (Cytosine Base Editor, CBE), designed specifically for the same species, CAR-T cells. In June of this year, the treatment was presented to the FDA for the treatment of relapsed or incurable T-ALL (acute Tlymphocyte leukaemia) and other CD7 malignant tumours, the first of which was the co-editor of four genes. The Chinese team found new potential targets for oncological immunotherapy. On 5 August, according to information from the Chinese University of Science and Technology, the team of Professor Zhou Yongbin of the Ministry of Life Sciences and Medicine and the team of Professor Jiangwei, in collaboration with the National Priority Laboratory for Transforming Medicine and Innovative Medicines, identified new potential targets for oncological immunotherapy. The study, published online in Science magazine on 4 August, in which researchers studied the role of the nerve stress centre in oncological immunity by constructing different oncology models, discovered the hypothalamus-trillus axis and the hormones it produced, α-MSH, which could contribute to the growth of tumours by promoting marrow blood and immunosuppressive marrow cells through its receptor MC5R, which is expected to be a potential new target for immunotherapy treatment of tumours. III. Financing and cooperation for oncology investment Sengine Precision Medicine received $10 million in A2 round financing to promote individualized cancer treatment In recent days, Sengine Precision Medicine, a precision oncology company based in Seattle, announced the completion of a $10 million A2 round of financing, which to date has totalled $19 million. Sengine Precision Medicine is a precision oncology company that uses patient-specific oncology cells to pre-test drugs on 3D cultures and to develop new cancer therapy. Sengine, the world-renowned derivative of the Fred Hutchinson Cancer Research Centre, has more than 20 years of research and development experience in diagnosis and drug discovery. The company is commercializing the PARIS tests, a next-generation diagnostic test for predicting drug response that combines knowledge of cancer genomics with the prototype tests of living cells derived from patients, using robotic techniques and know-how algorithms. Novasenta completed $40 million A-round financing for the development of new immuno-cancer candidate drugs Recently, Novasenta announced the completion of a $40 million A round of financing, led by a venture capital company, UPMC Enterprises. This funding will enable Novasenta to advance its antibody-based treatment, expand its proprietary computing platform for target discovery and continue to recruit top talent. The company’s team is using the human oncology micro-environment to develop new immunotherapy to enable humans’ own immune systems to combat cancer. The company has developed an exclusive platform for single-cell RNA analysis of human tumour samples that combines advanced data mining and target validation capabilities to accelerate the process from discovery to drug development. Inventive, venture capital co-directed, and the original creatures completed more than $120 million in B-round financing. In recent days, Innovative Biopharmaceuticals had announced the completion of a B round of financing totalling more than $120 million, which had been co-financed by pioneer and spring capital, with new investors in the Shanghai Initiative Fund, Kenichi Capital (the original drug capital), Suzhou Fund, Bozo Capital and a number of international investment funds, and the continued growth of new and emerging investments by old shareholders. This round of financing will be used primarily to facilitate the development and commercialization of more than a dozen fully conceptualized (POC) oncology treatment products, to continue to improve the construction of an autonomous corporate innovation technology platform, and to plan and build future commercial production bases. IDRx announced the completion of $122 million in round A financing, focusing on accurate cancer treatment. On 3 August, IDRx announced the completion of $122 million in round A financing. Building on the successful experience of therapeutic combination anti-cancer therapy and cocktail therapy in the treatment of cystic fibrosis and viral infections, IDRx aims to develop a highly selective, rationally designed combination of drugs to overcome the current limitations of precision anti-cancer drugs and to help more patients to achieve a more durable reduction in the early stages of the disease. The strategy of IDRx is to use combination therapy when cancer cells have not accumulated much mutation, which includes powerful targets to the main cancer-driven factors, and drugs to stop cancer cells from escaping. Conkwanda completes a new round of finance. Recently, Conwanda, the research and development developer of the soluble cancer virus, announced the completion of a new round of financing and strategic partnership introduction, with the participation of the East Heath Business Group, Chinese capital and the Blue Mountain Investment. It is understood that funds from this round of financing have been used mainly for technical development work such as clinical research and follow-up guidance virus product development for the new generation of cancer virus pipeline products in Conwanda. Konwanda Medical Science and Technology Ltd., Hangzhou, was established in February 2012 to work on the development of innovative drugs and treatments for somatic virus under the oncological immune theory, and Conwanda currently has seven somatic virus pipelines. Pan-Eun-Bio completes nearly a billion Pre-A round of financing. In recent days, the Guangzhou Pann Biotech Ltd. has completed nearly a billion yuan Pre-A round of financing. This round of financing will be financed by Chinese capital, Siovo, the Yabo pharmaceutical industry, and Japanese capital as an exclusive financial adviser, and will be used mainly for the IIND declaration and phase I clinical trials of multi-cell therapy products. The “Panese Organism” is mainly involved in the development of drugs for the treatment of oncology and related operations, and has developed autonomously a number of products for the treatment of oncology T-cells, as well as accurate screening of diagnostic reagents for the effective population of immunotherapy. He's working with Marengo Therapeutics. On 2 August, Ipsen and Marengo Therapeutics announced strategic cooperation to co-operate with Marengo's two pre-clinical selective T-cell receptor (TCR) activations. This collaboration will combine the expertise of Marengo in activating the T-cell innovation mechanism and the capacity for global oncology clinical development and commercialization. According to the agreement, Marengo will lead pre-clinical development activities until IIND applications are submitted to FDA in the United States, and Lippson will be responsible for clinical development and subsequent commercialization activities. Poseida Therapeutics entered into a partnership with Rhodes to develop a “ spot-based” CAR-T therapy On 4 August, Poseida Therapeutics announced a strategic cooperation and licensing agreement with Roche to cooperate in the development of the “sphere-type” amphibious CAR-T therapy for multiple osteoporomas, B-cell lymphoma and other blood adaptive disorders. Under this agreement, Poseida would receive an advance of $110 million, as well as recent milestones up to $110 million and other payments. Together with future development and commercialization milestones, Poseida would receive payments totalling up to $6 billion. Rhodes, on the other hand, will be given exclusive rights or options from Poseida for the development and commercialization of many Poseida projects on hemodynamic tumours of the same species, CAR-T, which include a clinical trial of the same species, CAR-T therapy P-BCMA-ALLO1, used for the treatment of multiple osteoporomas, as well as a projected IIND licence for the treatment of B-cell lymphoma in 2023, with the same species's double-targeting of CAR-T therapy P-CD19CD20-ALLO1. IV. 21CC week perspective Noise lymphoma is the first drug in Asia. Recently, Tafasitamab, an innovation for the treatment of lymphoma in Nouchen, has officially landed at the Hainan Hospital (hereinafter referred to as “Richin Hainan Hospital”) attached to the University of Shanghai Transport School of Medicine. At the same time, Tafasitamab opened in the vanguard of Bounty City and completed the first domestic injection at the Reginanan Hospital for a eligible Big B-cell lymphoma patient. “Tafasitamab’s initiative in Leisure City means that this innovative drug is being used for the first time in China to treat patients.” Dr. Choi Xiaozon, founder, chairman, and chief executive officer of the Nokchen Kenhua coalition, told the 21st Century economic reporter that it is a reflection of the full use of Lei Town’s concession policy, which allows more patients to benefit from Bo. Nocheng Kenhua is also in the process of submitting applications for the listing of new drugs in Hong Kong and Australia, which, once approved in Hong Kong and Australia, will benefit patients in the greater Gulf region, and is actively promoting the joint registration test of Tafasitamab in China, approved by the National Drug Control Service, while actively exploring the joint use of Obutoni and Tafasitamab. Professor Zhao Weiye Zhao, Vice-President of the Reginald Hospital, informed the 21st Century Economic Reporter that Tafasitamab was the new CD19 anti-innovation drug and that the first Asian patient had been reached by the Rigkin Hainan Hospital. In conjunction with the People's Hospital of Hainan Province, the Raking Hospital has established a national regional medical centre in Bojang, taking advantage of the policy advantages of the Pioneer City policy in Hainan. The hospital is a leading Chinese user of the new global medicine, a global promoter of the new Chinese medicine, a provider of the best medical care programme and a pioneer in the progress of clinical medicine worldwide. According to Lei Xiaorei, a member of the party committee and deputy director of the Lei Town Precinct Administration, to the 21st Century Economics Reporter, the company, including Noo Jianhua, has chosen Lei-City because of the gradual dividends of the Lei-City First Test policy, supported by health-related actions such as the Hainan Pharmacy Bureau, the National Pharmacy Bureau and the National Commission for Health Care, and especially since the establishment of the Le-Congree Administration, the Le-Congree Pre-Congree has made a “acccelerator” in the area of medical health, moving from a policy high to an industry-intensive “platform high ground”. “On this platform, the pharmaceutical industry, medical institutions and medical experts are actively involved and working closely together to bring the world's most advanced and innovative medical products, technologies and programmes to Le Lui City to meet the health needs of the population and to address the accessibility and affordability of medicines used by patients. The incidence of liver cancer in the stomach is underestimated, MUC 19 or an important biomarker. Recently, the internationally renowned journal, Chancer Communification (Impact Factors 15.28), published online a recent study by Professor Liu Tianshu of Nakayama Hospital, affiliated with the University of Khatami, in conjunction with the Medical Services, on the genetic mapping of the liver cancer in China and the important biomarker point MUC19, which drew molecular characteristics and development mechanisms for gastric hepatic cancer based on extraneous group data and provided important biological markers for the diagnosis and treatment of liver cancer in the stomach. Hepatitis cancer is known to be a rare but highly malignant form of stomach cancer, accounting for 0.3 to 1% of stomach cancer. In contrast to stomach cancer, hepatitis cancer is highly invasive, and patients are prone to liver and lymphosis, with very poor prognosis, with a 5-year survival rate of only 9%. Due to the low incidence of liver cancer in the stomach and its low clinical prevalence, it is rarely studied in depth, there is currently no standard treatment for liver cancer in the stomach, and the mechanisms for its occurrence are not well known. The above-mentioned study of this important biomarker MUC19 will probably boost the diagnosis and treatment of liver cancer in the stomach. To the twenty-first century economic report, Dr. Cumbung, a medical bioinformation scientist, told the economy that the current incidence of liver cancer in the stomach is understated and found that this biomarker is conducive to the diagnosis of patients who simply take blood for a rapid screening test to see if there is a mutation in the MUC19, which is equivalent to a diagnostic indication of a tumor that could become a cancer in the stomach liver. VI. Oncology knowledge point - hot target resolution CC21 will continue to launch the popular target study entitled " Review of the Clinical Study of New Anticancer Medicines in China 2021 ", published jointly by the Specialized Committee for Clinical Research on Anticancer Medicine of the China Society for the Advancement of Medical Innovation and the Heisco Research Foundation of Beijing. The above-mentioned associations and foundations aim to promote sound investment and research and development by investors and research and development institutions through annual reviews, by avoiding “high-level duplication” of overinvestment in popular areas and by paying attention to innovative areas that can fill clinical gaps, thereby optimizing the allocation of resources for research and development of new medicines for the sustainable development of China's pharmaceutical innovation industry. CCD7 1. Target mechanism Protein hormones associated with cell break-up cycle 7 (cell division cycle 7, CDC7) are a silicone/sultanic acid stimulant enzyme from yeast to humans, which plays a key role in the start-up of each replication starting point by being activated in conjunction with the active sub-unit Dbf4/S Ease Activator (ASK). There is growing evidence that CDC7 plays an important role in tumor cells, induces cell growth and may be associated with the prognosis of multiple malignant tumours. The CDC7 has been found to be highly expressed in the gelatinous breast tumor (GBM), which is associated with the poor prognosis of GBM patients. In addition, CDC7 induces radio-resistance from GBM cells, and CDC7 increases cell failure when it is removed from radiotherapy. CDC7 regulates the expression of DNA fix/reassemble 54L (RAD54L) by regulating RAD54L start-up activity. In treatment, CDC7 inhibitors inhibit the growth of tumor cells both in the body and in the body. 2. Overview of clinical research declarations A number of clinical studies on CDC7 targets are under way internationally, including Simurosertib (TAK-931), AS-0141, XL-413 but mostly I or I/II. At present, there are only very clean CDC7 inhibitors in the country who are conducting clinical studies for TQB3824 on safety and pharmacodynamic I among late-stage malignant tumour subjects. 3. Summary remarks There are currently fewer CDC7 targets for clinical research in the country, there are already distributed CDC7 inhibitors in domestic enterprises, such as redo medicine, and new generations of metabolic and stable CDC7 inhibitors still need more research and exploration to meet clinical needs. From impact mechanism analysis, CDC7 combined inhibitor treatment has the potential to reverse therapeutic resistance, and if combined DNA damage repair circuit inhibitors are likely to combine anti-cancer resistance, they can be actively explored in parallel with the accumulation of preliminary data during the single drug I period. (Revisitor, Beijing University Oncology Hospital, Gong Jiefan)

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.

Recent related articles

The same charge on different battlefields - a brief introduction to the deeds of "the most beautiful retired soldier" in 2022

2022-09-27: Ministry of Central Advocacy, Ministry of Veterans Affairs, Ministry of Political Work of the Central Military Commission Joint release of the 2022 Best Veterans. PLA newspaper Beijing, 21 September, journalist Zhang Peng Peung, reported that, in order to learn more and promote the…

Nancai Dialogue with 25 "Hong Kong" Innovation and Technology People ②丨 Exclusive interview with Yang Mengsu, Vice President of City University of Hong Kong: The role of colleges and universities in promoting innovation and technology is "indispensable"

2022-09-27: The HK Tech 300 scheme successfully filled the market fund gap, with 364 business teams known to have received HK$100,000 in seed funds and 73 start-up companies receiving up to HK$ 1,000,000 in angel fund investments Economic Reporter for the 21st Century, Juliana, Hong Kong. Entering an…  

21CC Tumor Intelligence (Issue 24): Zhou Yunshu, the former chairman of Hengrui Medicine, was fined for insider trading; Paterson, a minimally invasive tumor treatment company, plans to IPO in Hong Kong

2022-09-27: You can receive the latest information every week in the field of oncology. 21CC (cancercare), we are concerned with cancer-related matters. The Institute of New Health for the 21st Century's Innovation Information Program, 21CC Oncology Information, collating a week of information on tumours,…  

Featured Announcements丨Lixiang Auto expects the delivery volume to drop to 25,500 units in the third quarter; Tongxing Environmental receives a letter of concern: it is required to check whether there is a situation of cooperating with shareholders to reduce their holdings

2022-09-27: Today's Focus A letter of concern for the same environment: a request for verification of the existence of a stockholder's reduction. The company had previously disclosed that it had decided, together with the Chinese University of Science and Technology, to undertake research related to…  

Forward-looking confidence, value symbiosis! The 12th China Value Real Estate Annual Conference will kick off on September 29

2022-09-27: During this Annual Value Property Conference, we have specifically invited a number of high-profile guests in the real estate sector and will publish a number of heavy industry reports. Starting in August, we have organized several heavy-pound on-line pre-heating events, as well as a series of…  

The betel nut battle caused by the death of the 36-year-old singer: How does a first-class carcinogen grow into a net red food with an output value of 100 billion?

2022-09-27: titanium Media Note: This post is based on WeChat Public's 8-point news (ID: HealthInsight), by Chen Chang, Shakyi, Hwan, Li Lin, and is published with permission by titanium media. On September 10, 36-year-old singer Fosong died of oral cancer, stating on several occasions that the disease was…  

Qiu Yong is the Secretary of the Party Committee of the Shanghai Stock Exchange; the underwriting rate of financial bonds has broken the "floor price" again; the limited issuance of more than 500 billion yuan of special bonds will "open the gate"丨Da Asset Management Weekly Intelligence

2022-09-27: The 21st Century Institute of Investment and Management, Wu Shan, the intern's king. I. REGULATIONS AND POLICY 1. The China Silver Insurance Supervisory Board issued the Decision of the China Silver Insurance Supervisory Board to Amend the Regulations on Partial Administrative Permits The…  

Zao Cai 丨 Central Bank: The Financial Stability Fund has accumulated funds; Weimar’s annual loss of 8.2 billion is the founder’s annual salary of 1.2 billion? So it is; US spaceship will hit asteroid; Snowden gets Russian citizenship

2022-09-27: NO.1 On 26 September, the People's Bank of China sent a message that the Bank would further tighten the foundations of a sound financial operating system and secure the bottom line against systemic financial risks. In addition, in 2022, the People's Bank, in conjunction with the relevant…  

Zao Caijing丨Just now, the US spacecraft successfully hit the asteroid; Li Li was "double-opened"; the German Chancellor tested positive for the Covid virus; China and North Korea decided to restart the Dandong-Sinuiju port railway freight

2022-09-27: NBD Reporter, king sail, NBD Editor, Jan Jang, Wang Xiaobo, Ho Peach. NO.1 On 26 September, the People's Bank of China sent a message that the Bank would further tighten the foundations of a sound financial operating system and secure the bottom line against systemic financial risks. In…  

Recent related articles

The same charge on different battlefields - a brief introduction to the deeds of "the most beautiful retired soldier" in 2022

2022-09-27: Ministry of Central Advocacy, Ministry of Veterans Affairs, Ministry of Political Work of the Central Military Commission Joint release of the 2022 Best Veterans. PLA newspaper Beijing, 21 September, journalist Zhang Peng Peung, reported that, in order to learn more and promote the…

Nancai Dialogue with 25 "Hong Kong" Innovation and Technology People ②丨 Exclusive interview with Yang Mengsu, Vice President of City University of Hong Kong: The role of colleges and universities in promoting innovation and technology is "indispensable"

2022-09-27: The HK Tech 300 scheme successfully filled the market fund gap, with 364 business teams known to have received HK$100,000 in seed funds and 73 start-up companies receiving up to HK$ 1,000,000 in angel fund investments Economic Reporter for the 21st Century, Juliana, Hong Kong. Entering an…  

21CC Tumor Intelligence (Issue 24): Zhou Yunshu, the former chairman of Hengrui Medicine, was fined for insider trading; Paterson, a minimally invasive tumor treatment company, plans to IPO in Hong Kong

2022-09-27: You can receive the latest information every week in the field of oncology. 21CC (cancercare), we are concerned with cancer-related matters. The Institute of New Health for the 21st Century's Innovation Information Program, 21CC Oncology Information, collating a week of information on tumours,…  

Featured Announcements丨Lixiang Auto expects the delivery volume to drop to 25,500 units in the third quarter; Tongxing Environmental receives a letter of concern: it is required to check whether there is a situation of cooperating with shareholders to reduce their holdings

2022-09-27: Today's Focus A letter of concern for the same environment: a request for verification of the existence of a stockholder's reduction. The company had previously disclosed that it had decided, together with the Chinese University of Science and Technology, to undertake research related to…  

Forward-looking confidence, value symbiosis! The 12th China Value Real Estate Annual Conference will kick off on September 29

2022-09-27: During this Annual Value Property Conference, we have specifically invited a number of high-profile guests in the real estate sector and will publish a number of heavy industry reports. Starting in August, we have organized several heavy-pound on-line pre-heating events, as well as a series of…  

The betel nut battle caused by the death of the 36-year-old singer: How does a first-class carcinogen grow into a net red food with an output value of 100 billion?

2022-09-27: titanium Media Note: This post is based on WeChat Public's 8-point news (ID: HealthInsight), by Chen Chang, Shakyi, Hwan, Li Lin, and is published with permission by titanium media. On September 10, 36-year-old singer Fosong died of oral cancer, stating on several occasions that the disease was…  

Qiu Yong is the Secretary of the Party Committee of the Shanghai Stock Exchange; the underwriting rate of financial bonds has broken the "floor price" again; the limited issuance of more than 500 billion yuan of special bonds will "open the gate"丨Da Asset Management Weekly Intelligence

2022-09-27: The 21st Century Institute of Investment and Management, Wu Shan, the intern's king. I. REGULATIONS AND POLICY 1. The China Silver Insurance Supervisory Board issued the Decision of the China Silver Insurance Supervisory Board to Amend the Regulations on Partial Administrative Permits The…  

Zao Cai 丨 Central Bank: The Financial Stability Fund has accumulated funds; Weimar’s annual loss of 8.2 billion is the founder’s annual salary of 1.2 billion? So it is; US spaceship will hit asteroid; Snowden gets Russian citizenship

2022-09-27: NO.1 On 26 September, the People's Bank of China sent a message that the Bank would further tighten the foundations of a sound financial operating system and secure the bottom line against systemic financial risks. In addition, in 2022, the People's Bank, in conjunction with the relevant…  

Zao Caijing丨Just now, the US spacecraft successfully hit the asteroid; Li Li was "double-opened"; the German Chancellor tested positive for the Covid virus; China and North Korea decided to restart the Dandong-Sinuiju port railway freight

2022-09-27: NBD Reporter, king sail, NBD Editor, Jan Jang, Wang Xiaobo, Ho Peach. NO.1 On 26 September, the People's Bank of China sent a message that the Bank would further tighten the foundations of a sound financial operating system and secure the bottom line against systemic financial risks. In…